Transplant
News
Daratumumab approved in combo with VTd for transplant-eligible multiple myeloma
This marks the drug’s second approved indication this year and its seventh overall.
Feature
Ongoing research aims to improve transplant outcomes in sickle cell
Over the past 2 years, the majority of novel transplant techniques have been primarily aimed at improving conditioning regimens and lowering rates...
From the Journals
Several factors may affect immune suppression discontinuation after HCT
Older age, advanced stage disease, having a mismatched unrelated donor, and receiving peripheral blood stem cells from an unrelated donor were...
From the Journals
ASCT may cure follicular lymphoma for some rituximab-naive patients
A retrospective cohort study suggests that ASCT, if performed promptly, can be curative in patients who have had an early failure of first-line...
Feature
Could home care replace inpatient HSCT?
Researchers are conducting phase 2 trials comparing patients who receive all posttransplant care at home with patients treated in the hospital or...
From the Journals
VRD pretransplant induction deepens responses in myeloma
The researchers wrote that the unique dosing of the three-drug induction regimen may be considered a new standard of care.
From the Journals
Stem cells gene edited to be HIV resistant treat ALL, but not HIV
From the Journals
Nonmyeloablative conditioning carries lowers infection risk in patients with AML
Patients who received myeloablative conditioning tended to develop infections sooner.
From the Journals
Pediatric HSCT recipients still risking sunburn
Pediatric hematopoietic stem cell transplant recipients are practicing more sun-protection behaviors, but they still tan and sunburn as much as...
From the Journals
Progressive myeloma after induction? Go straight to transplant
The study did not find a survival advantage for patients who had salvage therapy to deepen their responses before moving on to transplant.
From the Journals
Novel conditioning regimen shows benefit for beta-thalassemia major
The transplant regimen significantly reduced graft-versus-host disease following unrelated-donor hematopoietic stem cell transplant.